Skip to contentA
Acro Biomedical Co., Ltd.
A
ACBMAcro Biomedical Co., Ltd. Q1 2024 · 10-Q
Revenue$0.00$0.00— vs Q1 2023 Net Income-$11.25K-$11.25KN/M vs Q1 2023 EPS Diluted$0.00$0.00N/M vs Q1 2023 Operating Income-$10,298N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Acro Biomedical Co., Ltd. · CIK 1622996 · Engraved from SEC EDGAR
ended Mar 31, 2024 · filed Jul 22, 2025 · 478 d after period end